Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

China

Peking Union Medical College Hospital, Beijing, Beijing Municipality

Peking University People's Hospital, Beijing, Beijing Municipality

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong